113 filings
Page 2 of 6
8-K
akhw2 tz08
15 May 23
Novan Reports First Quarter 2023 Financial Results and Provides
6:50am
8-K
eu19lby
7 Apr 23
Departure of Directors or Certain Officers
5:26pm
8-K
9wflh 58vizyvnl
30 Mar 23
Novan Reports Full Year 2022 Financial Results and Provides
6:36am
8-K
6pbcshnzra5h
16 Mar 23
Entry into a Material Definitive Agreement
4:21pm
8-K
q9twnfjx
13 Mar 23
Other Events
6:07am
8-K
9w5t9 15mpt7zlkh5ua
7 Mar 23
Results of Operations and Financial Condition
8:06am
8-K
4ks7ppfgc kk85x45
6 Jan 23
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
8:05am
8-K
b36tlo34 7kfl7ud
21 Dec 22
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADEĀ® in Japan
8:05am
8-K
zv6qep7g8wibifn7vqh
6 Dec 22
Entry into a Material Definitive Agreement
6:30am
8-K
w8r9c 8loze9t7nys
14 Nov 22
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:05am
8-K
pftjug30nmzdp3d
11 Aug 22
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:35am
8-K
4vrafw3
19 Jul 22
Termination of a Material Definitive Agreement
8:20am
8-K
2jikkrmmblfcy29ykw
10 Jun 22
Entry into a Material Definitive Agreement
4:11pm
8-K
gbiyr
8 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
uiz7uuar
20 May 22
Other Events
5:16pm
8-K
0dzofn
16 May 22
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
6:34am
8-K
cojcn9yaq by4j7
11 Mar 22
Entry into a Material Definitive Agreement
7:04am
8-K
vwm4lgm
11 Mar 22
Entry into a Material Definitive Agreement
6:43am
8-K
pkdt jmayj5ug6ke5y
30 Nov 21
Entry into a Material Definitive Agreement
4:06pm
8-K
la18dz0op ds
10 Nov 21
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
12:00am